Floatz logo

Sgr-1505

Splenic Marginal Zone Lymphoma

Schrödinger, Inc.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Splenic Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BB
Zanubrutinib
SWOG Cancer Research Network
Phase 3BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BB

View all 50 →

Same molecule, other indications

Sgr-1505 is also rated in:

MALT lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderlyDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →